Innate Pharma reports first half 2020 financial results and business update
Upcoming investor conferences
Number of shares and voting rights of Innate Pharma as at August 1, 2020
Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities
Innate Pharma announces publication of EXPLORE COVID-19 translational study findings in Nature
Innate Pharma announces the appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer
U.S. Food and Drug Administration lifts partial clinical hold on lacutamab TELLOMAK trial in advanced T-cell lymphomas
Outcome of Annual General Meeting of May 19, 2020
Innate Pharma to present new efficacy data for monalizumab in combination with cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program
Innate Pharma First Quarter 2020 Report
